ArticleMaedica2023
Atypical Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in an Elderly Lung Cancer Patient.
Article in Maedica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome develops in patients with various underlying diseases. The involvement of vascular endothelial growth factor in the development of this syndrome has been suggested and malignant disease could be one of the underlying diseases of RS3PE syndrome. This syndrome is interpreted as one of the paraneoplastic syndromes that often have a poor prognosis. There have been few reports of lung cancer patients who developed RS3PE syndrome, and the prognosis of these patients has been rarely discussed. The present case report describes a very elderly lung cancer patient with RS3PE syndrome. We believe he is the oldest patient with advanced lung cancer to have developed RS3PE syndrome. Edema of the dorsum of both hands disappeared by one month after the start of first-line chemotherapy. The relatively long disease control period of the first and later lines of chemotherapy led to a long-term survival of 45 months. The existence of a patient with such a slow clinical course should be considered valuable for future research. It is important to continue optimal treatment even in elderly patients with RS3PE syndrome, one of the paraneoplastic syndromes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.